Cyclic Nitrone Free Radical Traps: Isolation, Identification, and Synthesis of
3,3-Dimethyl-3,4-dihydroisoquinolin-4-ol N-Oxide, a Metabolite with Reduced
Side Effects
posted on 1996-12-06, 00:00authored byCraig E. Thomas, Patrick Bernardelli, S. Marc Bowen, Stephen F. Chaney, Dirk Friedrich, David A. Janowick, Bryan K. Jones, Frederick J. Keeley, John H. Kehne, Bert Ketteler, David F. Ohlweiler, Leo A. Paquette, David J. Robke, Thomas L. Fevig
A C-4 hydroxylated metabolite (2,
3,3-dimethyl-3,4-dihydroisoquinolin-4-ol N-oxide) of
the
previously described cyclic nitrone free radical trap 1
(3,3-dimethyl-3,4-dihydroisoquinoline
N-oxide, a cyclic analog of
phenyl-tert-butylnitrone (PBN)) was isolated, identified,
and
synthesized. The metabolite (2), though a less potent
antioxidant than 1 in an in vitro
lipid
peroxidation assay, showed greatly reduced acute toxicity and sedative
properties. Several
analogs of 2 were prepared in attempts to improve on its
weak antioxidant activity while
retaining the desirable side effect profile. Effective structural
changes included replacement
of the gem-dimethyl moiety with spirocycloalkane groups
and/or oxidation of the alcohols to
the corresponding ketones. All of the analogs were more lipophilic
(log k‘w) and more active in
the standard lipid peroxidation assay than 2. In
addition, some of the compounds were able
to protect cerebellar granule cells against oxidative damage (an
in vitro model of oxidative
brain injury) with IC50 values well below the value of the
lead compound 1. The ketones, as
predicted, were much more potent than 2 (and 1)
in both of the above assays (up to ca. 200-fold). However, only compounds with a hydroxyl or an acetate group
at C-4 displayed
significantly reduced acute toxicity and sedative properties relative
to those of 1. Importantly,
the diminishment of toxicity and sedation were not the result of a lack
of brain penetration as
both 2 and the corresponding ketone
(3,3-dimethyl-3,4-dihydro-3H-isoquinolin-4-one
N-oxide)
achieved equal or greater brain levels than those of 1 when
administered to rats ip.